Development and qualification of cell-based relative potency assay for a human respiratory syncytial virus (RSV) mRNA vaccine.

Saved in:
Bibliographic Details
Title: Development and qualification of cell-based relative potency assay for a human respiratory syncytial virus (RSV) mRNA vaccine.
Authors: Li HH; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA. Electronic address: hualin.li@merck.com., Xu J; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA., He L; Biostatistics and Research Decision Sciences, Merck & Co., Inc., West Point, PA 19486, USA., Denny LI; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA., Rustandi RR; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA., Dornadula G; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA., Fiorito B; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA., Zhang ZQ; Analytical Research and Development, Merck & Co., Inc., West Point, PA 19486, USA.
Source: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2023 Sep 20; Vol. 234, pp. 115523. Date of Electronic Publication: 2023 Jun 11.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-264X
DOI:10.1016/j.jpba.2023.115523